How valuable is ductal plate malformation as a predictor of clinical course in postoperative biliary atresia patients?
OBJECTIVE
We assessed ductal plate malformation (DPM) as a prognostic factor for mid-/long-term outcome in post-hepatoportoenterostomy (HPE) biliary atresia patients.


METHODS
Of 78 cases of HPE performed between 1989 and 2009, biopsy specimens were available for 43. Cytokeratin 19 was used to identify DPM and preoperative status, postoperative serum total bilirubin, time taken to become jaundice-free, duration of jaundice-free period, steroid usage, incidences of cholangitis, bile lakes, and varices, and requirement for reoperation and liver transplantation were compared.


RESULTS
DPM was detected in 21/43 (48.8%) subjects [DPM-positive (DPM+)]. Differences were identified for maximum postoperative serum total bilirubin: DPM+ (12.28 ± 1.00 mg/dL) versus DPM-negative (DPM-) (9.67 ± 0.71 mg/dL) (P < 0.05) and total steroid usage: DPM+ (98.3 ± 11.8 mg/kg) versus DPM- (83.4 ± 15.9 mg/kg) (P = NS). However, total steroid dose in jaundice-free cases was significantly higher in DPM+ [75.3 ± 10.0 mg/kg (n = 14) vs. 48.1 ± 6.4 mg/kg (n = 19); P < 0.05)]. There were no differences for complications. Mean duration of follow-up was significantly shorter for DPM+ (60.9 ± 38.4 vs. 113.8 ± 56.9 months; P < 0.05).


CONCLUSIONS
Postoperative total bilirubin was higher in DPM+ cases, thus higher doses of steroids were required. However, DPM+ did not appear to influence the incidence of complications mid-/long-term.
Department of Pediatric General and Urogenital Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Rumi
R
Arii
Hiroyuki
H
Koga
Atsushi
A
Arakawa
Katsumi
K
Miyahara
Geoffrey J
GJ
Lane
Tadaharu
T
Okazaki
Masahiko
M
Urao
Atsuyuki
A
Yamataka
D001652:Bile Ducts / Q000002:abnormalities*; D001653:Bile Ducts, Intrahepatic / Q000002:abnormalities; D001656:Biliary Atresia / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D001663:Bilirubin / Q000097:blood; D001706:Biopsy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000209:etiology; D008297:Male; D011171:Portoenterostomy, Hepatic; D011182:Postoperative Care / Q000379:methods; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D016896:Treatment Outcome
D005938:Glucocorticoids; D011239:Prednisolone; D001663:Bilirubin